NBY - NovaBay Pharmaceuticals, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD

NovaBay Pharmaceuticals, Inc.

2000 Powell Street
Suite 1150
Emeryville, CA 94608
United States

Full Time Employees86

Key Executives

NameTitlePayExercisedYear Born
Mr. Mark M. Sieczkarek M.B.A.Chairman, CEO & Pres453.5kN/A1955
Mr. John J. McGovernCFO & TreasurerN/AN/A1957
Mr. Justin M. HallSr. VP, Gen. Counsel & Corp. Sec.253.5kN/A1978
Dr. David W. StromanSr. VP of Ophthalmic Product Devel. & Chair of Ophthalmology Advisory BoardN/AN/A1945
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses. NovaBay Pharmaceuticals, Inc. has collaboration and license agreement with Virbac to develop auriclosene, a proprietary compound for veterinary markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.

Corporate Governance

NovaBay Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.